Articles Authored by Kelsy Ketchum
The team applied its method, which uses isothermal amplification and bioluminescent proteins, to SARS-CoV-2 detection.
The company's Q4 revenues grew 10 percent and full-year revenues increased 5 percent, exceeding analysts' average estimates.
The assay combines microfluidics, gene expression, and digital PCR to provide information on whether a patient's cancer has metastasized.
The company's test uses qPCR to measure the expression of two genes to determine the probability of sepsis.
Abbott Q4 Diagnostics Revenues Fall 26 Percent on Declining COVID-19 Sales
The company announced that its total revenues for the quarter declined 12 percent, while revenues for the full year rose 1 percent.
Danaher Q4 Revenues Rise 3 Percent Despite Difficulties in China
The firm's Life Sciences segment saw 8 percent growth year over year, while the Diagnostics sector rose 3 percent in the quarter.
PerkinElmer Becoming Pure Play Dx, Life Science Firm, Spurred on by COVID Innovations
At the JP Morgan conference, the firm's CEO said that it chose to divest its applied, food, and enterprise businesses due to innovations it achieved during the pandemic.
The company is planning to launch a 4-in-1 prenatal screening test, a liquid biopsy test, and a minimal residual disease assay in the coming year.
The firm has commercialized its pancreatic cancer test and has its sights set on an ovarian cancer test launching in 2023.
High payment rates for tests for rare disorders in regions covered by two Medicare Administrative Contractors could spark debate about genetic testing fraud.